<table id="table6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies [see<linkhtml href="#S12.3"> Clinical Pharmacology (12.3) </linkhtml>(<linkhtml href="#table12">Tables 12 </linkhtml>and<linkhtml href="#table13"> 13</linkhtml>) for magnitude of interaction]</caption>
<col align="left" span="1" valign="top" width="25%"></col>
<col align="left" span="1" valign="top" width="25%"></col>
<col align="left" span="1" valign="top" width="50%"></col>
<tbody>
<tr>
<th colspan="1">
<content stylecode="bold">Concomitant Drug Class:<br/>Drug Name</content>
</th>
<th colspan="1">
<content stylecode="bold">Effect on<br/>Concentration</content>
</th>
<th colspan="1">
<content stylecode="bold">Clinical Comment</content>
</th>
</tr>
<tr>
<th colspan="3">
<content stylecode="bold">HIV Antiviral Agents: Reverse Transcriptase Inhibitors</content>
</th>
</tr>
<tr>
<td>Delavirdine</td>
<td>↑ nelfinavir (C<sub>min</sub>)<br/>↓ delavirdine</td>
<td>Concentrations of nelfinavir were increased while concentrations of delavirdine were decreased when the two agents were coadministered. Appropriate doses of the combination, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>↓ nelfinavir (C<sub>min</sub>)</td>
<td>Concentrations of nelfinavir were decreased when coadministered with nevirapine. An appropriate dose of nelfinavir with respect to safety and efficacy has not been established.</td>
</tr>
<tr>
<td>Didanosine</td>
<td>↔ nelfinavir</td>
<td>There was no change in nelfinavir concentration when coadministered with didanosine. However, it is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be given one hour before or two hours after VIRACEPT (given with food).</td>
</tr>
<tr>
<td>
<content stylecode="bold">HIV Antiviral Agents: Protease Inhibitors</content>
</td>
</tr>
<tr>
<td>Indinavir</td>
<td>↑ nelfinavir<br/>↑ indinavir</td>
<td>Concentrations of both indinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>↑ nelfinavir<br/>↔ ritonavir</td>
<td>Concentrations of nelfinavir were increased when coadministered with ritonavir. An appropriate dose of nelfinavir for this combination, with respect to safety and efficacy, has not been established.</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>↑ nelfinavir<br/>↑ saquinavir</td>
<td>Concentrations of both saquinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr>
<td>
<content stylecode="bold">ANTICOAGULANT</content>
</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Warfarin</td>
<td>Coadministration of warfarin and VIRACEPT may affect concentrations of warfarin. It is recommended that the INR (international normalized ratio) be monitored carefully during treatment with VIRACEPT, especially when commencing therapy.</td>
</tr>
<tr>
<td>
<content stylecode="bold">ANTICONVULSANTS</content>
</td>
</tr>
<tr>
<td>Carbamazepine Phenobarbital<br/>Phenytoin</td>
<td>
<br/>↓ nelfinavir<br/>
<br/>↓ phenytoin</td>
<td>Concentrations of nelfinavir may be decreased. VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly.<br/>Phenytoin plasma/serum concentrations should be monitored; phenytoin dose may require adjustment to compensate for altered phenytoin concentration.</td>
</tr>
<tr>
<td>
<content stylecode="bold">ANTIDEPRESSANT</content>
</td>
</tr>
<tr>
<td>Trazodone</td>
<td>↑ trazodone</td>
<td>Concomitant use of trazodone and VIRACEPT may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as VIRACEPT, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr>
<td>
<content stylecode="bold">ANTIGOUT</content>
</td>
</tr>
<tr>
<td>Colchicine</td>
<td>↑ colchicines</td>
<td>Patients with renal or hepatic impairment should not be given colchicine with VIRACEPT due to the risk of colchicine toxicity.<br/>
<br/>Treatment of gout flares –<br/>co- administration of colchicine in patients on VIRACEPT:<br/>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br/>
<br/>Prophylaxis of gout-flares –<br/>coadministration of colchicine in patients on VIRACEPT:<br/>
<br/>
<br/>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<br/>Treatment of familial Mediterranean fever (FMF)– coadministration of colchicine in patients on VIRACEPT:<br/>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr>
<td>
<content stylecode="bold">ANTIMYCOBACTERIAL</content>
</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>↑ rifabutin<br/>↓ nelfinavir<br/>  (750 mg TID)<br/>↔ nelfinavir<br/>  (1250 mg BID)</td>
<td>It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT; 1250 mg BID is the preferred dose of VIRACEPT when coadministered with rifabutin.</td>
</tr>
<tr>
<td>
<content stylecode="bold">ENDOTHELIN RECEPTOR ANTAGONIST</content>
</td>
</tr>
<tr>
<td>Bosentan</td>
<td>↑ bosentan</td>
<td>Concentrations of bosentan may be increased when coadministered with VIRACEPT. Coadministration of bosentan in patients on VIRACEPT or coadministration of VIRACEPT in patients on bosentan:<br/>Start at or adjust bosentan to 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr>
<td>
<content stylecode="bold">HMG-CoA REDUCTASE INHIBITORS</content>
</td>
</tr>
<tr>
<td>Atorvastatin<br/>Rosuvastatin</td>
<td>↑ atorvastatin<br/>↑ rosuvastatin</td>
<td>Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.</td>
</tr>
<tr>
<td>
<content stylecode="bold">IMMUNOSUPPRESSANTS</content>
</td>
</tr>
<tr>
<td>Cyclosporine<br/>Tacrolimus<br/>Sirolimus</td>
<td>↑ immuno-suppressants<br/>↑ nelfinavir</td>
<td>Concentrations of these immunosuppressants and nelfinavir may be increased by coadministration of these agents with nelfinavir.</td>
</tr>
<tr>
<td>
<content stylecode="bold">INHALED BETA AGONIST</content>
</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>↑ salmeterol</td>
<td>Concurrent administration of salmeterol with VIRACEPT is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr>
<td>
<content stylecode="bold">INHALED/NASAL STEROID</content>
</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>↑ fluticasone</td>
<td>Concomitant use of fluticasone propionate and VIRACEPT may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.</td>
</tr>
<tr>
<td>
<content stylecode="bold">MACROLIDE ANTIBIOTIC</content>
</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>↑ azithromycin</td>
<td>Dose adjustment of azithromycin is not recommended, but close monitoring for known side effects such as liver enzyme abnormalities and hearing impairment is warranted.</td>
</tr>
<tr>
<td>
<content stylecode="bold">NARCOTIC ANALGESIC</content>
</td>
</tr>
<tr>
<td>Methadone</td>
<td>↓ methadone</td>
<td>Concentrations of methadone were decreased when coadministered with VIRACEPT. Dosage of methadone may need to be increased when coadministered with VIRACEPT.</td>
</tr>
<tr>
<td>
<content stylecode="bold">HORMONAL CONTRACEPTIVES</content>
</td>
</tr>
<tr>
<td>Ethinyl estradiol<br/>Norethindrone</td>
<td>↓ ethinyl estradiol<br/>↓ norethindrone</td>
<td>Concentrations of ethinyl estradiol and norethindrone were decreased when coadministered with VIRACEPT. Alternative or additional contraceptive measures should be used when oral contraceptives containing ethinyl estradiol or norethindrone and VIRACEPT are coadministered.</td>
</tr>
<tr>
<td>
<content stylecode="bold">PDE5 INHIBITORS</content>
</td>
</tr>
<tr>
<td>Sildenafil<br/>Vardenafil<br/>Tadalafil</td>
<td>↑ PDE5 Inhibitors</td>
<td>Concomitant use of PDE5 inhibitors and VIRACEPT should be undertaken with caution.<br/>
<br/>May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.<br/>
<br/>
<content stylecode="underline">Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH):</content>
<br/>
<br/>• Use of sildenafil (REVATIO) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) [<content stylecode="italics">see<linkhtml href="#S4"> Contraindications (4)</linkhtml>
</content>].<br/>
<br/>• The following dose adjustments are recommended for use of tadalafil (ADCIRCA™) with VIRACEPT:<br/>
<br/>
<content stylecode="underline">Coadministration of ADCIRCA in patients on VIRACEPT or coadministration of VIRACEPT in patients on ADCIRCA:</content>
<br/>
<br/>Start at or adjust ADCIRCA to 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">Use of PDE5 inhibitors for erectile dysfunction:</content>
<br/>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 24 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours, is recommended. Use with increased monitoring for adverse events.</td>
</tr>
<tr>
<td>
<content stylecode="bold">PROTON PUMP INHIBITORS</content>
</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>↓ nelfinavir</td>
<td>Omeprazole decreases the plasma concentrations of nelfinavir. Concomitant use of proton pump inhibitors and VIRACEPT may lead to a loss of virologic response and development of resistance.</td>
</tr>
</tbody>
</table>